A higher serum phosphorus level is associated with cardiovascular disease (CVD) events among communityliving populations. Mechanisms are unknown. The ankle-brachial index (ABI) provides information on both atherosclerosis and arterial stiffness. In this cross-sectional study (2000)(2001)(2002), the authors evaluated the association of serum phosphorus levels with low (<0.90) and high (1.40 or incompressible) ABI as compared with intermediate ABI in 5,330 older US men, among whom the mean serum phosphorus level was 3.2 mg/dL (standard deviation, 0.4), 6% had a low ABI, and 5% had a high ABI. Each 1-mg/dL increase in serum phosphorus level was associated with a 1.6-fold greater prevalence of low ABI (95% confidence interval (CI): 1.2, 2.1; P < 0.001) and a 1.4-fold greater prevalence of high ABI (95% CI: 1.0, 1.9; P ¼ 0.03) in models adjusted for demographic factors, traditional CVD risk factors, and kidney function. However, the association of phosphorus with high ABI differed by chronic kidney disease (CKD) status (in persons with CKD, prevalence ratio ¼ 2.96, 95% CI: 1.61, 5.45; in persons without CKD, prevalence ratio ¼ 1.14, 95% CI: 0.81, 1.61; interaction P ¼ 0.04). In conclusion, among communityliving older men, higher phosphorus levels are associated with low ABI and are also associated with high ABI in persons with CKD. These associations may explain the link between serum phosphorus levels and CVD events.
Cardiovascular disease (CVD) remains the leading cause of death in the United States (1) and an ever-increasing cause of death worldwide (2). Recently, serum phosphorus level has been identified as an independent risk factor for CVD events and mortality among community-living persons without chronic kidney disease (CKD) (3) (4) (5) . These associations are evident at serum phosphorus levels within the normal laboratory range (3) (4) (5) . Responsible mechanisms are uncertain. Vascular calcification and associated arterial stiffness is an attractive hypothesis, as in vitro studies have demonstrated that human aortic vascular smooth muscle cells calcify in response to extracellular phosphorus (6, 7) . Alternatively, serum phosphorus may accelerate the progression of atherosclerosis (8) .
The ankle-brachial index (ABI), defined as the ratio of systolic blood pressure in the ankle to that in the brachial artery, is a widely available noninvasive measure of peripheral arterial disease (PAD). An ABI less than 0.90 is sensitive and specific for flow-limiting atherosclerotic PAD by angiography (9) and has been strongly linked with future CVD events in a variety of clinical settings (10, 11) . On the other hand, high ABI measurements occur when lower limb arteries are calcified and stiff, thereby requiring higher cuff pressures to occlude the arteries in the ankle (12) . Studies among community-living adults predominantly without kidney disease have consistently demonstrated U-shaped relations between ABI measurements and CVD risk; subjects with either low or high ABI measurements are at approximately 2-fold greater risk of CVD events than those with intermediate ABI measurements (13) (14) (15) . In a small sample of participants in the Multi-Ethnic Study of Atherosclerosis, we observed an association of higher serum phosphorus levels with high ABI but not low ABI (16) . This observation led us to hypothesize that higher serum phosphorus levels may be uniquely associated with arterial calcification and stiffness but not with atherosclerosis. If so, peripheral arterial stiffness may represent a causal intermediary of the associations of higher phosphorus with CVD events (3) (4) (5) . However, the sample size in our prior study was relatively small, and few subjects had either high or low ABI measurements. To address this question in a larger study sample, we evaluated the association of serum phosphorus levels with high and low ABI among 5,330 community-living older men who participated in the Osteoporotic Fractures in Men (MrOS) Study.
MATERIALS AND METHODS

Study population
The MrOS Study is an ongoing multicenter observational study designed to evaluate risk factors for fracture in older men (17, 18) . Between March 2000 and April 2002, 5,995 men aged 65 years or older were recruited from 6 US clinical sites: Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; Pittsburgh, Pennsylvania; Portland, Oregon; and San Diego, California. Participant inclusion required: 1) the ability to walk without assistance; 2) the absence of bilateral hip replacements; 3) the ability to provide self-reported data and informed consent; 4) planned residence near a field center site for the duration of the study; and 5) the absence of any medical condition that would result in imminent death, as judged by the investigator. The institutional review board at each participating center approved the study protocol.
Questionnaires were used to obtain information about medical history, medication use, tobacco use, physical activity, and diet. Subjects provided fasting morning blood specimens and underwent ABI measurements at the study visit. For the present study, 167 subjects (2.8%) were excluded because of missing ABI measurements; 10 (0.2%) were excluded because of an ABI less than 0.90 in 1 leg and an incompressible artery in the other leg; 452 (7.5%) were excluded because of missing serum phosphorus measurements; and 36 (0.6%) were excluded because of missing covariate data. The resulting study sample for this analysis included 5,330 subjects.
Measurements
Serum phosphorus level. Serum phosphorus measurements were made from morning fasting blood specimens using a standard clinical automated analyzer (Roche COBAS Integra 800; Roche Diagnostics Corporation, Indianapolis, Indiana). Inter-and intraassay coefficients of variation were less than 3%, and the lower limit of detection was 0.3 mg/dL.
Ankle-brachial index. After the subject had rested supine for at least 5 minutes, systolic blood pressure was obtained at the right brachial artery and both ankles using a standard mercury sphygmomanometer and an 8-MHz Doppler probe. In the rare event that the right arm could not be used, the left arm was used. Two measurements were obtained at each site, and the mean systolic blood pressures in the brachial artery and both posterior tibial arteries were used to calculate leg-specific ABI. The lower of the 2 leg-specific ABIs was used as the index ABI for our analyses. If the lower limb artery could not be occluded despite inflating the leg blood pressure cuff to more than 300 mm Hg, the artery was deemed incompressible.
Other measurements. Participants completed a questionnaire at the baseline examination which asked about a physician's diagnosis of select medical conditions. Hypertension was defined by self-reported physician's diagnosis. Subjects were asked, ''Have you smoked at least 100 cigarettes (5 packs) in your entire life?'' and ''Do you smoke cigarettes now?'' Participants who responded ''yes'' to both questions were classified as current smokers, and those who answered ''yes'' only to the former question were classified as former smokers. Prevalent diabetes was defined as a fasting glucose concentration of 126 mg/dL or more, a selfreported history or physician's diagnosis of diabetes, or the use of oral hypoglycemic medication or insulin. Subjects' daily servings of fat and intakes of energy, calcium, and phosphorus were assessed by means of a modified Block Dietary Data Systems food frequency questionnaire (Block Dietary Data Systems, Berkeley, California). Data on all prescription medications recorded by the clinics were stored in an electronic medications inventory database (San Francisco Coordinating Center, San Francisco, California). Each medication was matched to its ingredient(s) on the basis of the Iowa Drug Information Service Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, Iowa) (19) . Physical activity was assessed using the Physical Activity Scale for the Elderly, as previously described (20) . Height and weight were measured with subjects wearing light clothes and no shoes, and body mass index was calculated as weight (kg)/height (m) 2 . Serum calcium, creatinine, high density lipoprotein cholesterol, total cholesterol, albumin, and alkaline phosphatase levels were measured using a Roche COBAS Integra 800 automated analyzer (Roche Diagnostics Corporation). Estimated glomerular filtration rate was calculated using the 4-variable Modification of Diet in Renal Disease equation (20) (21) (22) (23) ). An estimated glomerular filtration rate less than 60 mL/minute/1.73 m 2 was used to define CKD (24) .
Statistical analysis
Previous studies have consistently demonstrated ABI cutpoints of <0.90 and 1.40 as thresholds at which greater risks for CVD events and mortality are observed (14, 15) . Therefore, we categorized subjects according to these cutpoints a priori. Subjects were included in the high-ABI group if the lower of the 2 leg-specific ABI measurements was greater than or equal to 1.40 or if either leg artery was incompressible. Baseline differences in demographic and clinical variables were compared across ABI groups using analysis of variance or the Kruskal-Wallis test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables.
Multinomial logistic regression was used to evaluate the associations of serum phosphorus concentration with both high and low ABI simultaneously, compared with intermediate ABI. This model provides separate estimates of covariate associations with high and low ABI without the assumption of ordinality. Estimates are interpreted as prevalence ratios. Results from initial models were adjusted for age, race, and clinical field center site. In subsequent models, we added variables that differed across ABI groups in bivariate analyses (P < 0.05). We explored the functional form of the adjusted association of phosphorus with the continuous spectrum of ABI using generalized additive models with a smoother to fit cubic B-spline functions to the data. We created a multiplicative interaction term (CKD (estimated glomerular filtration rate < 60 mL/minute/ 1.73 m 2 vs. 60 mL/minute/1.73 m 2 ) 3 phosphorus) and included it in multivariable models to test for effect modification by CKD status. P values less than 0.05 were considered statistically significant for all comparisons, including the interaction term.
For comparison, the associations of serum calcium level with low and high ABI were evaluated using multinomial logistic regression models, as described above. Results were adjusted for the same covariates as those retained in the phosphorus models, to facilitate comparisons.
All analyses were performed using STATA, version 9.2 SE (Stata Corporation LP, College Station, Texas) and SPlus, version 6.1 (Insightful Corporation, Seattle, Washington).
RESULTS
As detailed above, 665 subjects (11%) were excluded because of missing measurements. These subjects were older and more frequently nonwhite than those retained for analysis. Percentages with low and high ABI were similar to those of subjects who were retained (Table 1) . Among the 5,330 study participants retained for analysis, the mean age was 73 years (standard deviation (SD), 6), and 90% were white. The mean serum phosphorus level was 3.2 mg/dL (SD, 0.4). A total of 328 participants (6%) had low ABI (<0.90), and 246 (5%) had high ABI (1.40 or incompressible). Among subjects with a high ABI, 81 (33%) were classified as such on the basis of incompressible arteries. The mean estimated glomerular filtration rate was 77 mL/minute/1.73 m 2 (SD, 18), and 903 participants (17%) had CKD (estimated glomerular filtration rate < 60 mL/ minute/1.73 m 2 ). As expected, participants with low ABI were older; more frequently nonwhite; had higher prevalences of diabetes, hypertension, and current smoking; were less physically active; had higher serum calcium and alkaline phosphatase levels and lower serum albumin levels; had a greater prevalence of CKD; and had lower dietary intakes of calcium and phosphorus (Table 2 ). In contrast, except for advanced age and diabetes, high ABI was not associated with traditional CVD risk factors. On average, subjects with high ABI were less likely to smoke and had lower total cholesterol levels, higher high density lipoprotein cholesterol levels, and a lower mean estimated glomerular filtration rate than those with intermediate ABI measurements.
We observed monotonic increases in the prevalence of both low and high ABI with higher serum phosphorus levels ( Figure 1) . In unadjusted models, each 1-mg/dL increase in serum phosphorus concentration was associated with more than 2-fold greater prevalence of low ABI and 1.5-fold greater prevalence of high ABI (Table 3) . After adjustment for age, race, and field center site, as well as in the final multivariable adjusted model, these associations were moderately attenuated but remained statistically significant for both extremes of ABI. Multivariable adjustment attenuated the association of serum phosphorus level with low ABI more so than with high ABI, such that in the fully adjusted model, each 1-mg/dL increase in serum phosphorus level was associated with an approximately 59% greater prevalence of low ABI and a 38% greater prevalence of high ABI. Thus, the multivariable model disclosed a U-shaped relation between serum phosphorus levels and the spectrum of ABI (Figure 2 ). However, while higher phosphorus levels were associated with low ABI regardless of CKD status (interaction P ¼ 0.67), the association of higher phosphorus levels with high ABI was more pronounced in persons with CKD (interaction P ¼ 0.04) ( Table 4) .
In companion analysis, we evaluated the association of serum calcium levels with low and high ABI. In unadjusted analysis, each 1-mg/dL increase in serum calcium level was associated with approximately 70% increased prevalence of low ABI but was not significantly associated with high ABI (Table 5) . Results were similar in multivariable models that adjusted for the same covariates as those used to evaluate serum phosphorus, and were also similar in persons with or without CKD (interaction P > 0.47).
DISCUSSION
Higher serum phosphorus levels were associated with low ABI in this cohort of community-living older men. Phosphorus levels were also associated with high ABI, an association that was stronger among persons with concomitant CKD. In each case, the associations were of moderate strength; showed a dose-response relation; were independent of estimated glomerular filtration rate, serum calcium level, and traditional CVD risk factors; and were observed for serum phosphorus levels within the normal laboratory range. These data demonstrate that serum phosphorus levels are associated with both atherosclerotic PAD and, in persons with CKD, peripheral arterial stiffness as well, which may inform mechanisms responsible for previously reported associations of phosphorus with CVD events.
Among persons with end-stage renal disease, higher serum phosphorus levels are associated with vascular calcification (25) . However, vascular calcification may represent either intimal calcification associated with atherosclerosis or medial arterial calcification-a distinct, non-flow-limiting vascular pathology in which calcium deposition is limited to the tunica media of the arterial wall. London et al. (26) demonstrated that higher phosphorus levels were strongly associated with medial arterial calcification, determined by a characteristic appearance on plain radiographs, in persons with end-stage renal disease. These observations are relevant to the current findings, because high ABI measurements and leg systolic blood pressures greater than 190 mm Hg are highly specific for radiographically determined medial arterial calcification (12) . However, persons with endstage renal disease frequently have high serum phosphorus levels and extensive vascular calcification and are at extremely high risk for CVD events in comparison with community-living persons without kidney disease (27) . Few studies have evaluated the associations of serum phosphorus with vascular calcification or stiffness in other settings. In approximately 1,300 participants in the Multi-Ethnic Study of Atherosclerosis, we observed a strong association of higher phosphorus levels with high ABI; however, few subjects had high ABI in this cohort of middle-aged persons without prevalent CVD (16) . The present study confirms these findings in a substantially larger sample but suggests that the relation may be particularly pronounced in persons with concomitant CKD.
Why would the association of serum phosphorus with high ABI be stronger in persons with CKD? One possibility The spline function (solid line) was adjusted for age, race, field center site, diabetes, hypertension, smoking, physical activity, total cholesterol, high density lipoprotein cholesterol, estimated glomerular filtration rate, dietary calcium, dietary phosphorus, alkaline phosphatase, serum albumin, and serum calcium. Dotted lines, 95% confidence interval. is that persons with CKD may have diminished renal reserve for excretion of excess phosphorus. While phosphorus levels are typically maintained in the normal laboratory range until advanced stages of CKD (28), it is possible that dietary phosphorus load may lead to transient increases in serum phosphorus level in these persons, leading to a greater time-averaged exposure to serum phosphorus, even if fasting phosphorus levels are similar to those of persons without CKD. Alternatively, components of the early uremic milieu may interact with serum phosphorus to enhance medial calcium deposition, which in turn may lead to peripheral arterial stiffness and high ABI measurements (29) .
Contrary to our initial hypothesis, we observed that higher serum phosphorus levels were also associated with low ABI measurements, irrespective of CKD status. An ABI measurement less than 0.90 is a sensitive and specific marker of flow-limiting atherosclerotic PAD by angiography (9) . Thus, the association of phosphorus with low ABI suggests that higher phosphorus levels may be linked with atherosclerosis. Few investigators have evaluated the association of serum phosphorus with subclinical atherosclerosis. London et al. (26) demonstrated that higher phosphorus levels were associated with carotid intima-media thickness in persons with end-stage renal disease. Similarly, among communityliving participants in the Atherosclerosis Risk in Communities Study (mean estimated glomerular filtration rate ¼ 93.1 mL/minute/1.73 m 2 ), higher phosphorus levels were also associated with higher carotid intima-media thickness in men, but not in women (8) . Recently, Foley et al. (4) demonstrated an association of higher serum phosphorus levels with coronary artery calcification among young communityliving participants without kidney disease. To our knowledge, only 2 prior studies have evaluated the association of phosphorus levels with low ABI. One was our pilot study in the Multi-Ethnic Study of Atherosclerosis cohort, described previously (16) . The other evaluated approximately 5,000 National Health and Nutrition Examination Survey participants (30) . In both cases, no association of serum phosphorus levels and low ABI was observed in either unadjusted or adjusted analyses. Differences in study design may account for the discrepant findings reported here. Participants in both prior studies were younger and included approximately 50% women. In the National Health and Nutrition Examination Survey populations, subjects over age 60 years had only 1 ankle blood pressure measurement, which may have resulted in some misclassification. Our prior analysis of data from the Multi-Ethnic Study of Atherosclerosis excluded subjects with clinical CVD and included only 59 subjects with low ABI (16) . The present study provided a substantially larger sample size. Nonetheless, given the discrepant findings, future studies are needed to confirm this finding.
Lower-limb arterial stiffness and atherosclerosis can coexist within individuals. In 2 recent studies, investigators evaluated persons referred to vascular laboratories for clinically suspected PAD (31, 32) . More than half of subjects with high ABI measurements were found to have concomitant atherosclerotic PAD by other confirmatory diagnostic tests (31, 32) . These studies were conducted within referral populations. While the prevalence of concomitant high ABI and atherosclerotic PAD may be lower in community-living populations, it is possible that the association of phosphorus and high ABI observed herein reflects underlying and undetected atherosclerotic PAD. Lower limb vascular stiffness may have obscured the detection of atherosclerosis in these persons. Future studies with confirmatory tests for atherosclerotic PAD among persons with high ABI, such as toe brachial index measurements (31, 32) , are required to determine whether the association of serum phosphorus with lower limb arterial stiffness is independent of coexisting atherosclerosis.
Strengths of this study included its large sample size, its community-living and geographically diverse population, and the availability of demographic and laboratory measurements of potentially confounding variables. However, the study also had important limitations. ABI or phosphorus measurements were not available for 11% of the cohort, which may have introduced selection bias into our study. These data should be confirmed in other settings. Participants were all older, male, free-living, and able to walk without assistance, and most were white; the results may not be generalizable to other populations. The study lacked secondary confirmatory tests for atherosclerotic PAD among persons with high ABI measurements. Data on other markers of mineral metabolism, such as vitamin D and parathyroid hormone levels, were not available. We cannot exclude the possibility of confounding by these or other unmeasured variables. The cross-sectional study design did not allow evaluation of the temporal relation of the observed associations. Lastly, there is misclassification inherent with arterial stiffness. Some participants with low ABI may have some arterial stiffness, but not enough to bias the ABI toward normal or high levels. Conversely, some participants may have both atherosclerosis and arterial stiffness in balance with resultant intermediate ABI. Any such misclassification, however, should have biased our results toward the null hypothesis.
We conclude that higher serum phosphorus levels are associated with low ABI, and with high ABI among persons with concomitant CKD, in community-living older men. Because atherosclerosis and lower limb arterial stiffness may coexist within individuals, future studies are required to determine whether the association of phosphorus with high ABI is independent of concomitant atherosclerotic PAD. In addition, investigators in future studies should evaluate whether serum phosphorus contributes to CVD events through arterial stiffness, atherosclerosis, or both in concert.
